Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD's The Liver Meeting® 2023 -November 10, 2023 at 08:02 am EST

Vir Biotechnology, Inc. today announced that it will be presenting new data from its Phase 2 trials evaluating the potential clinical impact that VIR-3434 and VIR-2218 could have for chronic...

Related Keywords

Auckland ,New Zealand ,Boston ,Massachusetts ,United States ,Paris ,France General ,France ,Clichy ,Ukraine ,Edward Gane ,Tarik Asselah ,Exchange Commission ,Nasdaq ,University Of Auckland ,Alnylam Pharmaceuticals Inc ,Vir Biotechnology Inc ,University Of Paris ,Vir Biotechnology ,American Association ,Liver Diseases ,Without Pegylated Interferon ,Results After ,Late Breaking Poster Session ,Chief Hepatologist ,Transplant Physician ,Deputy Director ,New Zealand Liver Transplant Unit ,Auckland City Hospital ,Monoclonal Antibody ,Chronic Hepatitisd Virus ,Preliminary Results ,Late Breaking Parallel Session ,Viral Hepatitis ,Enhanced Stabilization Chemistry Plus ,Alnylam Pharmaceuticals ,Private Securities Litigation Reform Act ,Markets ,